GHRP-2 5 mg

GHRP-2 5 mg contains pralmorelin, a growth hormone secretagogue peptide. In research settings it is used to stimulate GH release via ghrelin receptor activation. In non-medical bodybuilding contexts, GHRP-2 is commonly referenced for its GH-stimulating properties, though such use falls outside approved indications.

Community protocols commonly reference GHRP-2 being injected 1–3 times daily at doses of 100–200 mcg per injection. Doses are typically timed on an empty stomach to maximize the GH response. The GH pulse from GHRP-2 is short-lived, which is why multiple daily doses are used to create multiple pulses.

GHRP-2 does not suppress endogenous testosterone production because it acts on the ghrelin receptor rather than directly affecting the hypothalamic-pituitary-gonadal axis. Post-cycle therapy is therefore generally not considered necessary after GHRP-2 use alone.

GHRP-2 stimulates growth hormone release by activating the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus. This produces a pulsatile GH release that mimics the body's natural secretion pattern. GHRP-2 also has moderate effects on appetite, cortisol, and prolactin.

The GH pulse from a single GHRP-2 injection typically peaks within 15–30 minutes and returns to baseline within a few hours. Effects on GH levels are therefore acute and short-lived with each dose. Any cumulative effects on physique or recovery would develop over weeks of consistent use.

There is no single GH secretagogue that is universally best. GHRP-2 occupies a middle ground between Ipamorelin (more selective, less potent) and GHRP-6 (more potent, more appetite stimulation). The appropriate choice depends on individual goals and priorities.

Both GHRP-2 and GHRP-6 are growth hormone secretagogues, but they differ in their side effect profiles. GHRP-6 produces more pronounced appetite stimulation, while GHRP-2 has a more moderate effect on appetite. GHRP-2 is generally considered more selective with less cortisol and prolactin elevation than GHRP-6.

GHRP-2 is more potent for GH release but less selective, producing moderate cortisol and prolactin elevations. Ipamorelin is more selective with minimal effects on these hormones but produces a smaller GH pulse. GHRP-2 is positioned between ipamorelin and GHRP-6 in terms of selectivity versus potency.

100 mcg is commonly referenced as the saturation dose for GHRP-2, meaning the point beyond which additional peptide produces diminishing GH response. Doses of 100–200 mcg per injection are typical in community protocols. The 5 mg vial contains 5,000 mcg total, providing 25–50 doses at these levels.

GHRP-2 5 mg is labeled at 5 mg of GHRP-2 per vial. It is supplied as a lyophilized powder in a 2 mL vial, requiring reconstitution before use.

Yes. A published laboratory report dated November 7, 2025 measured GHRP-2 5 mg at 5.88 mg, equivalent to 117.6% of its 5 mg label claim. The batch number for this report is #HDGH10.

The complete report can be viewed in the Lab Reports tab. Laboratory results apply to the tested sample represented by the individual report and should not be interpreted as a measurement of every vial.

Lyophilized GHRP-2 is typically reconstituted with a suitable solvent such as Bacteriostatic Water or sterile water. The volume of solvent added determines the concentration of the resulting solution. Proper sterile technique should be used during reconstitution.